COSCIENS Biopharma Optimistic Despite Q2 Loss
Company Announcements

COSCIENS Biopharma Optimistic Despite Q2 Loss

COSCIENS Biopharma (TSE:CSCI) has released an update.

COSCIENS Biopharma Inc. reported increased revenues and a net loss in Q2 2024, with a strong cash position of $27.8 million. The company is progressing with post-merger integration and cost-saving strategies, focusing on growth through its diversified biopharmaceutical portfolio. Notably, COSCIENS anticipates releasing pivotal data from the DETECT-Trial for macimorelin, a diagnostic for childhood-onset growth hormone deficiency, in the third quarter.

For further insights into TSE:CSCI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCOSCIENS Biopharma Restructures Board After Resignation
TheFlyCosciens Biopharma director Carolyn Egbert resigns
TipRanks Auto-Generated NewsdeskCOSCIENS Biopharma Welcomes New Board Director
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App